Isoniazid monotherapy versus other monotherapies or combination chemotherapy for preventing active tuberculosis in HIV-negative persons

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2009, Pages

  Sharma, Surendra K ^a   Sharma, Anju ^b   Kadhiravan, Tamilarasu ^a   Tharyan, Prathap ^c  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

^c CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ANOREXIA; ARTHRALGIA; CHEMOPROPHYLAXIS; CHILL; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; DIARRHEA; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DYSMENORRHEA; EPIGASTRIC PAIN; FATIGUE; FEVER; HEADACHE; HIGH RISK PATIENT; HUMAN; HYPERSENSITIVITY REACTION; HYPERURICEMIA; INSOMNIA; LIVER TOXICITY; MALAISE; MONOTHERAPY; NAUSEA; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PRURITUS; RASH; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT DURATION; TUBERCULOSIS; VOMITING; WEIGHT REDUCTION;

EID: 70249094606     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007545     Document Type: Review

References (24)

1. American Thoracic Society. Diagnostic standards and classification of tuberculosis. American Review of Respiratory Disease 1990;142(3):725-735
2. ATS/CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. Morbidity and Mortality Weekly Report Recommendations and Reports 2000;49(RR-6):1-51.
3. Balcells 2006 Balcells ME, Thomas SL, Godfrey-Faussett P, Grant AD. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerging Infectious Diseases 2006;12(5):744-751 (Pubitemid 43726847)
4. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al.American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. American Journal of Respiratory and Critical Care Medicine 2003;167(4):603-662
5. Cook 2006 Cook PP, Maldonado RA, Yarnell CT, Holbert D. Safety and completion rate of short-course therapy for treatment of latent tuberculosis infection. Clinical Infectious Diseases 2006;43(3):271-275 (Pubitemid 44078895)
6. Dye 1999 Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999;282(7):677-686 (Pubitemid 29384157)
7. Ena 2005 Ena J, Valls V. Short-course therapy with rifampin plus isoniazid compared with standard therapy with isoniazid for latent tuberculosis Infection: a meta-analysis. Clinical Infectious Diseases 2005;40(5):670-676 (Pubitemid 40381339)
8. Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C. Tuberculosis. Lancet 2003;362(9387):887-899
9. Gao 2006 Gao XF, Wang L, Liu GJ, Wen J, Sun X, Xie Y, et al.Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis. International Journal of Tuberculosis and Lung Disease 2006;10(10):1080-1090 (Pubitemid 44519344)
10. Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors), Cochrane Handbook of Systematic Reviews of Intervention. Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
11. Jasmer RM, Nahid P, Hopewell PC. Latent tuberculosis infection. New England Journal of Medicine 2002;347(23):1860-1866
12. Lardizabal 2006 Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman LB. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest 2006;130(6):1712-1717 (Pubitemid 46033423)
13. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
14. LoBue 2003 LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. American Journal of Respiratory and Critical Care Medicine 2003;168(4):443-447 (Pubitemid 37046873)
15. Marais 2006 Marais BJ, van Zyl S, Schaaf HS, van Aardt M, Gie RP, Beyers N. Adherence to isoniazid preventive chemotherapy: a prospective community based study. Archives of Disease in Childhood 2006;91(9):762-765 (Pubitemid 44351177)
16. McElroy 2005 McElroy PD, Ijaz K, Lambert LA, Jereb JA, Iademarco MF, Castro KG, et al.National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection. Clinical Infectious Diseases 2005;41(8):1125-1133 (Pubitemid 41429475)
17. National Institute for Health and Clinical Excellence, National Collaborating Centre for Chronic Conditions. Management of latent tuberculosis. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London: Royal College of Physicians, 2006:105-114
18. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
19. Sepkowitz KA, Raffalli J, Riley L, Kiehn TE, Armstrong D. Tuberculosis in the AIDS era. Clinical Microbiology Reviews 1995;8(2):180-199
20. Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database of Systematic Reviews 1999, Issue 1. [DOI: 10.1002/14651858.CD001363]
21. van Zyl 2006 van Zyl S, Marais BJ, Hesseling AC, Gie RP, Beyers N, Schaaf HS. Adherence to anti-tuberculosis chemoprophylaxis and treatment in children. International Journal of Tuberculosis and Lung Disease 2006;10(1):13-18 (Pubitemid 43266271)
22. World Health Organization Stop TB Partnership Childhood TB Subgroup. Chapter 4: childhood contact screening and management. International Journal of Tuberculosis and Lung Disease 2007;11(1):12-15
23. World Health Organization. Key points. Global tuberculosis control: surveillance, planning, financing; WHO report 2008 [WHO/HTM/TB/2008. 393]. Geneva: World Health Organization, 2008:3-6.
24. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: 10.1002/14651858.CD000171.pub2]